- Home
- ELWS vs PPBT Comparison
ELWS vs PPBT Comparison
Compare ELWS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- PPBT
- Stock Information
- Founded
- ELWS 2018
- PPBT 2010
- Country
- ELWS Japan
- PPBT Israel
- Employees
- ELWS N/A
- PPBT N/A
- Industry
- ELWS
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- PPBT Health Care
- Exchange
- ELWS Nasdaq
- PPBT Nasdaq
- Market Cap
- ELWS 6.2M
- PPBT 7.1M
- IPO Year
- ELWS 2023
- PPBT N/A
- Fundamental
- Price
- ELWS $2.15
- PPBT $2.68
- Analyst Decision
- ELWS
- PPBT Strong Buy
- Analyst Count
- ELWS 0
- PPBT 1
- Target Price
- ELWS N/A
- PPBT $33.00
- AVG Volume (30 Days)
- ELWS 12.5K
- PPBT 10.3K
- Earning Date
- ELWS 03-03-2025
- PPBT 03-10-2025
- Dividend Yield
- ELWS N/A
- PPBT N/A
- EPS Growth
- ELWS N/A
- PPBT N/A
- EPS
- ELWS N/A
- PPBT N/A
- Revenue
- ELWS $2,292,406.00
- PPBT N/A
- Revenue This Year
- ELWS N/A
- PPBT N/A
- Revenue Next Year
- ELWS N/A
- PPBT N/A
- P/E Ratio
- ELWS N/A
- PPBT N/A
- Revenue Growth
- ELWS 404.13
- PPBT N/A
- 52 Week Low
- ELWS $1.04
- PPBT $2.00
- 52 Week High
- ELWS $8.68
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- ELWS 44.92
- PPBT 42.85
- Support Level
- ELWS $2.01
- PPBT $2.64
- Resistance Level
- ELWS $2.39
- PPBT $2.93
- Average True Range (ATR)
- ELWS 0.25
- PPBT 0.15
- MACD
- ELWS 0.05
- PPBT 0.01
- Stochastic Oscillator
- ELWS 43.73
- PPBT 10.15
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.